Theranostics is an emerging paradigm that combines imaging and therapy in order to
personalize patient treatment. In nuclear medicine, this is achieved by using …

The objective of this study was to determine the safety, kinetics, and dosimetry of the 177Lu-
labeled prostate-specific membrane antigen (PSMA) small molecules 177Lu-PSMA I&T and …

Radiopharmaceutical therapy using α-particle emitting radionuclides (αRPT) is a novel
treatment modality that delivers highly potent alpha-particles to cancer cells or their …

The assessment of gliomas by 18F-FDOPA PET imaging as an adjunct to MRI showed high
performance by combining static and dynamic features to noninvasively predict the isocitrate …

Introduction Estimation of accurate time-integrated activity coefficients (TIACs) and radiation
absorbed doses (ADs) is desirable for treatment planning in peptide-receptor radionuclide …

Radiopharmaceutical therapies (RPTs) with 177Lu-prostate-specific membrane antigen
(PSMA) ligands have demonstrated promising results for the treatment of metastatic …

Objective. This study considers the error distributions for time-integrated activity (TIA) of
single-time-point (STP) methods for patient-specific dosimetry in radionuclide therapy …

Radiopharmaceuticals used for cancer therapy are highly selective, designed to kill
malignant cells and spare healthy tissues. Side effect rates are generally less than other …

Purpose This project aims to develop and evaluate a method for accurately determining time-
integrated activities (TIAs) in single-time-point (STP) dosimetry for molecular radiotherapy. It …

Personalized dose-based treatment planning requires accurate and reproducible
noninvasive measurements to ensure safety and effectiveness. Dose estimation using …